BR112022020683A2 - Anticorpos e composições anti-flt3 - Google Patents
Anticorpos e composições anti-flt3Info
- Publication number
- BR112022020683A2 BR112022020683A2 BR112022020683A BR112022020683A BR112022020683A2 BR 112022020683 A2 BR112022020683 A2 BR 112022020683A2 BR 112022020683 A BR112022020683 A BR 112022020683A BR 112022020683 A BR112022020683 A BR 112022020683A BR 112022020683 A2 BR112022020683 A2 BR 112022020683A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- flt3 antibodies
- flt3
- antibodies
- cancer
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/74—Inducing cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063009578P | 2020-04-14 | 2020-04-14 | |
| PCT/EP2021/059646 WO2021209495A1 (en) | 2020-04-14 | 2021-04-14 | Anti-flt3 antibodies and compositions |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022020683A2 true BR112022020683A2 (pt) | 2022-11-29 |
Family
ID=75530015
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022020683A BR112022020683A2 (pt) | 2020-04-14 | 2021-04-14 | Anticorpos e composições anti-flt3 |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US12252539B2 (https=) |
| EP (1) | EP4136114A1 (https=) |
| JP (1) | JP7679399B2 (https=) |
| KR (1) | KR20220167331A (https=) |
| CN (1) | CN115715297A (https=) |
| AU (1) | AU2021255884A1 (https=) |
| BR (1) | BR112022020683A2 (https=) |
| CA (1) | CA3180188A1 (https=) |
| CL (1) | CL2022002833A1 (https=) |
| CO (1) | CO2022014520A2 (https=) |
| IL (1) | IL297269A (https=) |
| MX (1) | MX2022012919A (https=) |
| PE (1) | PE20230075A1 (https=) |
| PH (1) | PH12022552710A1 (https=) |
| TW (1) | TWI910146B (https=) |
| WO (1) | WO2021209495A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI910146B (zh) * | 2020-04-14 | 2026-01-01 | 法商施維雅藥廠 | 抗flt3抗體及組合物 |
| WO2024108163A2 (en) * | 2022-11-18 | 2024-05-23 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Molecules that bind to cd135 polypeptides |
| EP4637816A1 (en) * | 2022-12-22 | 2025-10-29 | The Medical College of Wisconsin, Inc. | Compositions that target cd138 and cd3 and methods of making and using the same |
| IL325858A (en) * | 2023-07-12 | 2026-03-01 | Phenomic Ai | Mediators of T cell activation against CTHRC1 and methods of using them |
| CN118924724B (zh) * | 2024-07-29 | 2025-11-04 | 湖南大学 | 一种用于治疗神经母细胞瘤的药物组合物 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7832394A (en) | 1993-09-08 | 1995-03-27 | Imclone Systems Incorporated | Monoclonal antibodies that recognize flk-2 receptors and the isolation of primitive hematopoietic stem cell populations |
| US5635388A (en) | 1994-04-04 | 1997-06-03 | Genentech, Inc. | Agonist antibodies against the flk2/flt3 receptor and uses thereof |
| EP1105427A2 (en) | 1998-08-17 | 2001-06-13 | Abgenix, Inc. | Generation of modified molecules with increased serum half-lives |
| MXPA03003632A (es) | 2000-10-24 | 2003-09-10 | Immunex Corp | Metodo para tratamiento de tumores usando terapia de combinacion. |
| AR071891A1 (es) | 2008-05-30 | 2010-07-21 | Imclone Llc | Anticuerpos humanos anti-flt3 (receptor tirosina cinasa 3 tipo fms humano) |
| HRP20160422T1 (hr) * | 2009-12-23 | 2016-05-20 | Synimmune Gmbh | Protutijela protiv flt3 postupci njihove upotrebe |
| CA2961950A1 (en) * | 2014-09-28 | 2016-03-31 | The Regents Of The University Of California | Modulation of stimulatory and non-stimulatory myeloid cells |
| TWI829617B (zh) * | 2015-07-31 | 2024-01-21 | 德商安美基研究（慕尼黑）公司 | Ｆｌｔ３及ｃｄ３抗體構築體 |
| AU2017382883B2 (en) * | 2016-12-21 | 2024-07-04 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Human monoclonal antibodies specific for FLT3 and uses thereof |
| CN118772278A (zh) * | 2017-06-02 | 2024-10-15 | 辉瑞公司 | Flt3的特异性抗体及其用途 |
| JP7317718B2 (ja) * | 2017-06-02 | 2023-07-31 | ファイザー・インク | Ｆｌｔ３を標的にするキメラ抗原受容体 |
| CN113056486B (zh) * | 2018-09-11 | 2025-06-17 | 德国肿瘤研究中心 | 改善的抗flt3抗原结合蛋白 |
| JP7642542B2 (ja) * | 2018-12-18 | 2025-03-10 | ベーリンガー・インゲルハイム・イオ・カナダ・インコーポレイテッド | Ｆｌｔ３アゴニスト抗体及びその使用 |
| TWI910146B (zh) * | 2020-04-14 | 2026-01-01 | 法商施維雅藥廠 | 抗flt3抗體及組合物 |
-
2021
- 2021-04-14 TW TW110113434A patent/TWI910146B/zh active
- 2021-04-14 IL IL297269A patent/IL297269A/en unknown
- 2021-04-14 WO PCT/EP2021/059646 patent/WO2021209495A1/en not_active Ceased
- 2021-04-14 US US17/230,289 patent/US12252539B2/en active Active
- 2021-04-14 BR BR112022020683A patent/BR112022020683A2/pt unknown
- 2021-04-14 PE PE2022002250A patent/PE20230075A1/es unknown
- 2021-04-14 EP EP21718860.6A patent/EP4136114A1/en active Pending
- 2021-04-14 MX MX2022012919A patent/MX2022012919A/es unknown
- 2021-04-14 CN CN202180042192.0A patent/CN115715297A/zh active Pending
- 2021-04-14 AU AU2021255884A patent/AU2021255884A1/en active Pending
- 2021-04-14 PH PH1/2022/552710A patent/PH12022552710A1/en unknown
- 2021-04-14 CA CA3180188A patent/CA3180188A1/en active Pending
- 2021-04-14 KR KR1020227039594A patent/KR20220167331A/ko active Pending
- 2021-04-14 JP JP2022562446A patent/JP7679399B2/ja active Active
-
2022
- 2022-10-13 CO CONC2022/0014520A patent/CO2022014520A2/es unknown
- 2022-10-14 CL CL2022002833A patent/CL2022002833A1/es unknown
-
2025
- 2025-02-07 US US19/048,584 patent/US20250179195A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| TW202200620A (zh) | 2022-01-01 |
| PE20230075A1 (es) | 2023-01-11 |
| US12252539B2 (en) | 2025-03-18 |
| CA3180188A1 (en) | 2021-10-21 |
| WO2021209495A1 (en) | 2021-10-21 |
| CN115715297A (zh) | 2023-02-24 |
| JP2023522630A (ja) | 2023-05-31 |
| MX2022012919A (es) | 2022-11-16 |
| CO2022014520A2 (es) | 2022-11-08 |
| TWI910146B (zh) | 2026-01-01 |
| CL2022002833A1 (es) | 2023-06-09 |
| US20210317216A1 (en) | 2021-10-14 |
| AU2021255884A1 (en) | 2022-11-17 |
| US20250179195A1 (en) | 2025-06-05 |
| EP4136114A1 (en) | 2023-02-22 |
| IL297269A (en) | 2022-12-01 |
| KR20220167331A (ko) | 2022-12-20 |
| PH12022552710A1 (en) | 2024-03-25 |
| JP7679399B2 (ja) | 2025-05-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022020683A2 (pt) | Anticorpos e composições anti-flt3 | |
| BR112023024772A2 (pt) | Anticorpos anti-nkg2a e composições | |
| EA201890009A1 (ru) | Ингибиторы ezh2 для лечения лимфомы | |
| MX2022003895A (es) | Metodos para mejorar la terapia de bloqueo del punto de control inmune mediante la modulacion del microbioma. | |
| EA201991985A1 (ru) | Конъюгаты антитело-лекарственное средство (калс) на основе ингибиторов гдац и применение в терапии | |
| JOP20180008A1 (ar) | مركبات لعلاج إصابة بعدوى فيروس الالتهاب الكبدي b | |
| CY1121849T1 (el) | Μεθοδοι και συνθεσεις για τη θεραπεια του καρκινου | |
| MX2016007351A (es) | Terapia de combinacion para tratar cancer. | |
| EA201990951A1 (ru) | Комбинации, содержащие ssao/vap-1 ингибитор и sglt2-ингибитор, и их применение | |
| MX392779B (es) | Anticuerpos anti-cd27 | |
| MX383866B (es) | Inhibidores de ezh2 para tratar linfomas. | |
| EA201890571A1 (ru) | Способы и композиции для лечения нарушения, ассоциированного с геном пропротеинконвертазы субтилизин/кексинового типа (pcsk9) | |
| EA201790195A1 (ru) | Способы лечения рака с применением ингибиторов tigit и противораковых агентов | |
| EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
| EA201690754A1 (ru) | Применение ингибитора pcsk9 для лечения гиперлипидемии | |
| BR112015005772A2 (pt) | método para a intensificação de imunoterapias específicas no tratamento de câncer | |
| ZA201700196B (en) | Methods for treating high cardiovascular risk patients with hypercholesterolemia | |
| BR112015008447A2 (pt) | métodos para tratar câncer | |
| EA201591786A1 (ru) | Монотерапия gla для применения в лечении рака | |
| EA201790142A1 (ru) | Лечение лейкоза ингибиторами гистондеацетилазы | |
| EA201591925A1 (ru) | Терапевтические композиции и их применение | |
| BR112018074619A2 (pt) | uso de um anticorpo anti-pd-1 em combinação com um anticorpo anti-cd30 em tratamento com câncer | |
| MX2019003722A (es) | Composiciones inmunogénicas de tert y métodos de tratamiento que las utilizan. | |
| MX2016011667A (es) | Composiciones topicas que comprenden un extracto de coriolus versicolor para aumentar la autoinmunidad. | |
| EA202091112A1 (ru) | Сокристаллы, фармацевтические композиции на их основе и способы лечения, предусматривающие их применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B154 | Notification of filing of divisional application [chapter 15.50 patent gazette] |
Free format text: O PEDIDO FOI DIVIDIDO NO BR122025028949-3 PROTOCOLO 870250119268 EM 23/12/2025 18:11. |